Reflections on Atherosclerosis: Lesson from the Past and Future Research Directions

References

• Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association [published correction appears in Circulation. Circulation. 2019;139(10):e56–e528. doi:10.1161/CIR.0000000000000659
   PubMed Web of Science ®Google Scholar
• Murphy WA Jr, Zur Nedden D, Gostner P, Knapp R, Recheis W, Seidler H. The Iceman: discovery and imaging. Radiology. 2003;226(3):614–629.
   PubMed Web of Science ®Google Scholar
• Czermak J. Description and microscopic findings of two Egyptian mummies. Meet Acad Sci. 1852;9:27–69.
   Google Scholar
• Smith GE. 61079: the mummy of Menephtah. In: Smith GE, editor. The Royal Mummies. Cairo, Egypt: Imprimerie de l’Institut Francais d’Archeologic Orientale; 1912:65–70.
   Google Scholar
• Shattock SG. A report upon the pathological condition of the Aorta of King Menephtah, traditionally regarded as the Pharaoh of the Exodus. Proc R Soc Med. 1909;2(PatholSect):122–127.
   Google Scholar
• Sandison AT. Sir Marc Armand Ruffer (1859-1917) pioneer of palaeopathology. Med Hist. 1967;11(2):150‐156. doi:10.1017/s002572730001200x
   Google Scholar
• Ruffer MA. Remarks on the histology and pathological anatomy of Egyptian mummies. Cairo Sci J. 1910;4:40.
   Google Scholar
• Ruffer MA. On arterial lesions found in Egyptian mummies (1580 B.C.—525 A.D.). J Pathol Bacteriol. 1911;16:453–462. doi:10.1002/path.1700150403
   Google Scholar
• Long AR Cardiovascular renal disease: a report of a case three thousand years ago. Arch Pathol (Chic) 1931; 12:92–94
   Google Scholar
• Allam AH, Thompson RC, Wann LS, et al. Atherosclerosis in ancient Egyptian mummies: the Horus study. JACC Cardio-Vasc Imaging. 2011;4(4):315–327.
   Web of Science ®Google Scholar
• Thompson RC, Allam AH, Lombardi GP, et al. Atherosclerosis across 4000 years of human history: the Horus study of four ancient populations. Lancet. 2013;381(9873):1211–1222. doi:10.1016/S0140-6736(13)60598-X
   PubMed Web of Science ®Google Scholar
• Allam AH, Mandour Ali MA, Wann LS, et al. Atherosclerosis in ancient and modern Egyptians: the Horus study. Glob Heart. 2014;9(2):197–202. doi:10.1016/j.gheart.2014.03.2454
   Google Scholar
• Thompson RC, Allam AH, Zink AR, et al. Computed tomographic evidence of atherosclerosis in the mummified remains of humans from around the world. Glob Heart. 2014;9(2):187–196. doi:10.1016/j.gheart.2014.03.2455
   Google Scholar
• David AR, Kershaw A, Heagerty A. Atherosclerosis and diet in ancient Egypt. The Lancet. 2010;375(9716):718–719. doi:10.1016/S0140-6736(10)60294-2
   PubMed Web of Science ®Google Scholar
• Minelli P, Montinari MR. The mediterranean diet and cardioprotection: historical overview and current research. J Multidiscip Healthc. 2019;12:805–815. doi:10.2147/JMDH.S219875
   Web of Science ®Google Scholar
• Thomas GS, Wann LS, Allam AH, et al. Why did ancient people have atherosclerosis? From autopsies to computed tomography to potential causes. Glob Heart. 2014;9(2):229–237. doi:10.1016/j.gheart.2014.04.002
   Google Scholar
• Rocha e Silva M. A brief survey of the history of inflammation. Agents Actions. 1978;8(1–2):45–49. doi:10.1007/bf01972401
   Google Scholar
• Rather LJ. Disturbance of function (functio laesa): the legendary fifth cardinal sign of inflammation, added by Galen to the four cardinal signs of Celsus. Bull N Y Acad Med. 1971;47(3):303–322.
   Google Scholar
• Davies MK, Eollman A. Leonardo da Vinci (1452–1519). Heart. 1996;76(6):464. doi:10.1136/hrt.76.6.464
   Web of Science ®Google Scholar
• Leibowitz J. The History of Coronary Disease. London: Wellcome Institute of the History of Medicine; 1970:107.
   Google Scholar
• André E Jean-Frédéric Lobstein: “Artériosclérose” et “ostéoporose”, Historie des Sciences Medicales - Tome LII - N° 2, 197-208, 2018.
   Google Scholar
• Mönckeberg JG, Die Reine Ü. Mediaverkalkung der Extremitätenarterien und ihr Verhalten zur Arteriosklerose. Virchows Arch Path Anat. 1903;171:141–167. doi:10.1007/BF01926946
   Google Scholar
• Marchand F. Ueber Atherosclerosis. Vol. 21. Kongresse: Verhandlungen der Kongresse fuer Innere Medizin; 1904.
   Google Scholar
• Virchow R. Cellular Pathology. London, United Kingdom: John Churchill; 1858.
   Google Scholar
• Rokitansky K, Day EG, Moore HC, Sieveking EH, Swaine EW. A Manual of Pathological Anatomy. Philadelphia: Blanchard & Lea; 1855:201–205.
   Google Scholar
• Virchow R. Phlogose und Thrombose im Gefasssystem. Gesammelte Abhandlungen zur Wissenschaftlichen Medicin. Frankfurt: Meidinger Sohn and Co.; 1856:p 458.
   Google Scholar
• Virchow R. Der Ateromatose Prozess der Arterien. Wien Med Wochenschr. 1856:825–827.
   Google Scholar
• Duguid JB. Pathogenesis of arteriosclerosis. Lancet. 1949;2:925–927. doi:10.1016/S0140-6736(49)91503-2
   PubMed Web of Science ®Google Scholar
• French JE. Atherosclerosis in relation to the structure and function of the arterial intima, with special reference to the endothelium. Int Rev Exp Pathol. 1966;5:253–353.
   Google Scholar
• Mustard JF, Packham MA. The role of blood and platelets in atherosclerosis and the complications of atherosclerosis. Thromb Diath Haemor. 1975;33:444–456. doi:10.1055/s-0038-1647838
   PubMedGoogle Scholar
• Wissler RW. Development of the atherosclerosis plaque. In: Braunwald E, editor. The Myocardium: Failure and Infarction. New York: H.P. Publishing Co; 1974:155–166.
   Google Scholar
• Thomas WA, Jones R, Scott RF, Morrison E, Goodale F, Imai H. Production of early atherosclerotic lesions in rats characterized by proliferation of “modified smooth muscle cells. Exp Mol Pathol. 1963;2(suppl 1):40–61. doi:10.1016/0014-4800(63)90005-4
   Google Scholar
• Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science. 1973;180(4093):1332–1339. doi:10.1126/science.180.4093.1332
   Web of Science ®Google Scholar
• Ross R. Rous-Whipple Award Lecture. Am J Pathol. 1993;143(4):987–1002.
   Google Scholar
• Ross R. Atherosclerosis-an inflammatory disease. Atherosclerosis: a defense mechanism gone awry. N Engl J Med. 1999;340(2):115–126. doi:10.1056/NEJM199901143400207
   PubMed Web of Science ®Google Scholar
• Windaus A. Ueber der Gehalt normaler und ateromatoser Aorten an Colesterolo und colesterinester. Zeitschrift Physiol Chemie. 1910;67:174. doi:10.1515/bchm2.1910.67.2.174
   Google Scholar
• Anichkov NN. Experimental arteriosclerosis in animals. In: Cowdry EV, editor. Arteriosclerosis: A Survey of the Problem. New York: MacMillan Publishing; 1933:271–322.
   Google Scholar
• Anichkov NN. A history of experimentation on arterial atherosclerosis in animals. In: Blumenthal HT, editor. Cowdry’s Arteriosclerosis: A Survey of the Problem. 2nd ed. Springfield, (IL): Charles C Thomas Publishing; 1967:21–46.
   Google Scholar
• Dock W. Research in arteriosclerosis; the first fifty years. Ann Intern Med. 1958;49:699–707. doi:10.7326/0003-4819-49-3-699
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Brown MS. Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc Natl Acad Sci U S A. 1973;70(10):2804–2808. doi:10.1073/pnas.70.10.2804
   Web of Science ®Google Scholar
• Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett. 1976;72(2):323–326. doi:10.1016/0014-5793(76)80996-9
   PubMed Web of Science ®Google Scholar
• Brown MS, Faust JR, Goldstein JL, Kaneko I, Endo A. Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J Biol Chem. 1978;253(4):1121–1128.
   PubMed Web of Science ®Google Scholar
• Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–156. doi:10.1038/ng1161
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Hegele RA, Fazio S, Cannon CP. The evolving future of PCSK9 inhibitors. J Am Coll Cardiol. 2018;72(3):314–329. doi:10.1016/j.jacc.2018.04.054
   PubMed Web of Science ®Google Scholar
• Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol. 2003;91(3A):3A–6A. doi:10.1016/s0002-9149(02)03143-0
   Google Scholar
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–1695. doi:10.1056/NEJMra043430
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–874. doi:10.1038/nature01323
   PubMed Web of Science ®Google Scholar
• Gimbrone MAJr, Topper JN, Nagel T, Anderson KR, Garcia-Cardeña G. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann NY Acad Sci. 2000;902:230–240. doi:10.1111/j.1749-6632.2000.tb06318.x
   PubMed Web of Science ®Google Scholar
• Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004;109(23Suppl 1):III27–III32. doi:10.1161/01.CIR.0000131515.03336.f8
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Nierman MC, Stroes ES, Kastelein JJ, Duriez P. New risk factors for atherosclerosis and patient risk assessment. Circulation. 2004;109(23Suppl 1):III15–III19. doi:10.1161/01.CIR.0000131513.33892.5b
   Web of Science ®Google Scholar
• Libby P, Hansson GK. From focal lipid storage to systemic inflammation: JACC review topic of the week. J Am Coll Cardiol. 2019;74(12):1594–1607. doi:10.1016/j.jacc.2019.07.061
   Web of Science ®Google Scholar
• Libby P, Hansson GK. Inflammation and immunity in diseases of the arterial tree: players and layers. Circ Res. 2015;116:307–311. doi:10.1161/CIRCRESAHA.116.301313
   PubMed Web of Science ®Google Scholar
• Ketelhuth DFJ, Lutgens E, Bäck M, et al. Immunometabolism and atherosclerosis: perspectives and clinical significance: a position paper from the Working Group on Atherosclerosis and Vascular Biology of the European Society of Cardiology. Cardiovasc Res. 2019;115(9):1385–1392. doi:10.1093/cvr/cvz166
   Web of Science ®Google Scholar
• Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12:204–212. doi:10.1038/ni.2001
   PubMed Web of Science ®Google Scholar
• Zhao TX, Mallat Z. Targeting the immune system in atherosclerosis: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(13):1691–1706. doi:10.1016/j.jacc.2018.12.083
   Web of Science ®Google Scholar
• Feldman N, Rotter-Maskowitz A, Okun E. DAMPs as mediators of sterile inflammation in aging-related pathologies. Ageing Res Rev. 2015;24:29–39. doi:10.1016/j.arr.2015.01.003
   PubMed Web of Science ®Google Scholar
• Sellge G, Kufer TA. PRR-signaling pathways: learning from microbial tactics. Semin Immunol. 2015;27:75–84. doi:10.1016/j.smim.2015.03.009
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805‐820. doi:10.1016/j.cell.2010.01.022
   Web of Science ®Google Scholar
• Lin J, Kakkar V, Lu X. Essential roles of toll-like receptors in atherosclerosis. Curr Med Chem. 2016;23(5):431‐454. doi:10.2174/0929867323666151207111408
   Web of Science ®Google Scholar
• Tabas I, García-Cardeña G, Owens GK. Recent insights into the cellular biology of atherosclerosis. J Cell Biol. 2015;209(1):13–22. doi:10.1083/jcb.201412052
   PubMed Web of Science ®Google Scholar
• Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56. doi:10.1038/s41572-019-0106-z
   PubMed Web of Science ®Google Scholar
• Gimbrone MA Jr, García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016;118(4):620–636. doi:10.1161/CIRCRESAHA.115.306301
   PubMed Web of Science ®Google Scholar
• Libby P, DiCarli M, Weissleder R. The vascular biology of atherosclerosis and imaging targets. J Nucl Med. 2010;51(Suppl 1):33S–37S. doi:10.2967/jnumed.109.069633
   Web of Science ®Google Scholar
• Hua J, Malinski T. Variable effects of LDL subclasses of cholesterol on endothelial nitric oxide/peroxynitrite balance - the risks and clinical implications for cardiovascular disease. Int J Nanomedicine. 2019;14:8973–8987. doi:10.2147/IJN.S223524
   PubMed Web of Science ®Google Scholar
• Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27(11):2292–2301. doi:10.1161/ATVBAHA.107.149179
   PubMed Web of Science ®Google Scholar
• Habas K, Shang L. Alterations in intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) in human endothelial cells. Tissue Cell. 2018;54:139–143. doi:10.1016/j.tice.2018.09.002
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Hansson GK. Leducq transatlantic network on atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129–2138. doi:10.1016/j.jacc.2009.09.009
   PubMed Web of Science ®Google Scholar
• Ramji DP, Davies TS. Cytokines in atherosclerosis: key players in all stages of disease and promising therapeutic targets. Cytokine Growth Factor Rev. 2015;26(6):673–685. doi:10.1016/j.cytogfr.2015.04.003
   PubMed Web of Science ®Google Scholar
• Trus E, Basta S, Gee K. Who’s in charge here? Macrophage colony stimulating factor and granulocyte macrophage colony stimulating factor: competing factors in macrophage polarization. Cytokine. 2020;127:154939. doi:10.1016/j.cyto.2019.154939
   Web of Science ®Google Scholar
• Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol. 2010;7(2):77–86. doi:10.1038/nrcardio.2009.228
   PubMed Web of Science ®Google Scholar
• Basatemur GL, Jørgensen HF, Clarke MCH, Bennett MR, Mallat Z. Vascular smooth muscle cells in atherosclerosis. Nat Rev Cardiol. 2019;16(12):727–744. doi:10.1038/s41569-019-0227-9
   PubMed Web of Science ®Google Scholar
• Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in atherosclerosis: from mice to humans [published correction appears in Immunity. Immunity. 2013;38(6):1092–1104. doi:10.1016/j.immuni.2013.06.009
   PubMed Web of Science ®Google Scholar
• Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013;13:709–721. doi:10.1038/nri3520
   PubMed Web of Science ®Google Scholar
• Abdolmaleki F, Gheibi Hayat SM, Bianconi V, Johnston TP, Sahebkar A. Atherosclerosis and immunity: a perspective. Trends Cardiovasc Med. 2019;29(6):363–371. doi:10.1016/j.tcm.2018.09.017
   PubMed Web of Science ®Google Scholar
• Swirski FK, Robbins CS, Nahrendorf M. Development and function of arterial and cardiac macrophages. Trends Immunol. 2016;37(1):32–40. doi:10.1016/j.it.2015.11.004
   PubMed Web of Science ®Google Scholar
• Ammirati E, Moroni F, Magnoni M, Camici PG. The Role of T and B cells in human atherosclerosis and atherothrombosis. Clin Exp Immunol. 2015;179:173–187. doi:10.1111/cei.12477
   PubMed Web of Science ®Google Scholar
• Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013;13(3):159–175. doi:10.1038/nri3399
   PubMed Web of Science ®Google Scholar
• Silvestre-Roig C, Braster Q, Ortega-Gomez A, et al. Neutrophils as regulators of cardiovascular inflammation. Nat Rev Cardiol. 2020. doi:10.1038/s41569-019-0326-7
   Web of Science ®Google Scholar
• Ilatovskaya DV, Halade GV, DeLeon-Pennell KY. Adaptive immunity-driven inflammation and cardiovascular disease. Am J Physiol Heart Circ Physiol. 2019;317(6):H1254–H1257. doi:10.1152/ajpheart.00642.2019
   Web of Science ®Google Scholar
• Ketelhuth DF, Hansson GK. Adaptive response of T and B cells in atherosclerosis. Circ Res. 2016;118(4):668–678. doi:10.1161/CIRCRESAHA.115.306427
   PubMed Web of Science ®Google Scholar
• Tabas I, Lichtman AH. Monocyte-macrophages and T cells in atherosclerosis. Immunity. 2017;47(4):621–634. doi:10.1016/j.immuni.2017.09.008
   PubMed Web of Science ®Google Scholar
• Bartlett B, Ludewick HP, Misra A, Lee S, Dwivedi G. Macrophages and T cells in atherosclerosis: a translational perspective. Am J Physiol Heart Circ Physiol. 2019;317(2):H375–H386. doi:10.1152/ajpheart.00206.2019
   Web of Science ®Google Scholar
• Ou HX, Guo BB, Liu Q, et al. Regulatory T cells as a new therapeutic target for atherosclerosis. Acta Pharmacol Sin. 2018;39(8):1249–1258. doi:10.1038/aps.2017.140
   PubMed Web of Science ®Google Scholar
• Srikakulapu P, McNamara CA. B cells and atherosclerosis. Am J Physiol Heart Circ Physiol. 2017;312(5):H1060–H1067. doi:10.1152/ajpheart.00859.2016
   Web of Science ®Google Scholar
• Sage AP, Tsiantoulas D, Binder CJ, Mallat Z. The role of B cells in atherosclerosis. Nat Rev Cardiol. 2019;16(3):180–196. doi:10.1038/s41569-018-0106-9
   PubMed Web of Science ®Google Scholar
• Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991‐1045. doi:10.1146/annurev.iy.12.040194.005015
   Web of Science ®Google Scholar
• Liu D, Zeng X, Li X, Mehta JL, Wang X. Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases. Basic Res Cardiol. 2018;113:5. doi:10.1007/s00395-017-0663-9
   PubMed Web of Science ®Google Scholar
• Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019;20(13):3328. doi:10.3390/ijms20133328
   PubMed Web of Science ®Google Scholar
• Jiang X, Wang F, Wang Y, et al. Inflammasome-Driven Interleukin-1α and Interleukin-1β production in atherosclerotic plaques relates to hyperlipidemia and plaque complexity. JACC Basic Transl Sci. 2019;4(3):304–317. doi:10.1016/j.jacbts.2019.02.007
   Google Scholar
• Satish M, Agrawal DK. Atherothrombosis and the NLRP3 inflammasome - endogenous mechanisms of inhibition. Transl Res. 2020;215:75–85. doi:10.1016/j.trsl.2019.08.003
   Web of Science ®Google Scholar
• Kaplan H, Thompson RC, Trumble BC, et al. Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study. Lancet. 2017;389(10080):1730–1739. doi:10.1016/S0140-6736(17)30752-3
   PubMed Web of Science ®Google Scholar
• Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162(4):597–605. doi:10.1016/j.ahj.2011.06.012
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–1131. doi:10.1056/NEJMoa1707914
   PubMed Web of Science ®Google Scholar
• Ridker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319–328. doi:10.1016/S0140-6736(17)32814-3
   PubMed Web of Science ®Google Scholar
• Abderrazak A, Couchie D, Mahmood DF, et al. Anti-inflammatory and antiatherogenic effects of the NLRP3 inflammasome inhibitor arglabin in ApoE2.Ki mice fed a high-fat diet. Circulation. 2015;131(12):1061–1070. doi:10.1161/CIRCULATIONAHA.114.013730
   Web of Science ®Google Scholar
• Nidorf SM, Fiolet ATL, Eikelboom JW, et al. The effect of low-dose colchicine in patients with stable coronary artery disease: the LoDoCo2 trial rationale, design, and baseline characteristics. Am Heart J. 2019;218:46–56. doi:10.1016/j.ahj.2019.09.011
   PubMed Web of Science ®Google Scholar
• Wu LM, Wu SG, Chen F, et al. Atorvastatin inhibits pyroptosis through the lncRNA NEXN-AS1/NEXN pathway in human vascular endothelial cells. Atherosclerosis. 2020;293:26–34. doi:10.1016/j.atherosclerosis.2019.11.033
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380(8):752–762. doi:10.1056/NEJMoa1809798
   PubMed Web of Science ®Google Scholar
• Ridker PM. Anticytokine agents: targeting interleukin signaling pathways for the treatment of atherothrombosis. Circ Res. 2019;124(3):437–450. doi:10.1161/CIRCRESAHA.118.313129
   PubMed Web of Science ®Google Scholar
• Fernandez DM, Rahman AH, Fernandez NF, et al. Single-cell immune landscape of human atherosclerotic plaques. Nat Med. 2019;25(10):1576‐1588. doi:10.1038/s41591-019-0590-4
   Web of Science ®Google Scholar
• Winkels H, Ehinger E, Vassallo M, et al. Atlas of the immune cell repertoire in mouse atherosclerosis defined by single-cell RNA-sequencing and mass cytometry. Circ Res. 2018;122(12):1675‐1688. doi:10.1161/CIRCRESAHA.117.312513
   Web of Science ®Google Scholar
• Willemsen L, de Winther MP. Macrophage subsets in atherosclerosis as defined by single-cell technologies. J Pathol. 2020;250(5):705‐714. doi:10.1002/path.5392
   Web of Science ®Google Scholar
• Roy P, Ali AJ, Kobiyama K, Ghosheh Y, Ley K. Opportunities for an atherosclerosis vaccine: from mice to humans [published online ahead of print, 2020 Jan 18]. Vaccine. 2020;S0264-410X(19):31681. doi:10.1016/j.vaccine.2019.12.039
   Web of Science ®Google Scholar
• Kobiyama K, Saigusa R, Ley K. Vaccination against atherosclerosis. Curr Opin Immunol. 2019;59:15–24. doi:10.1016/j.coi.2019.02.008
   PubMed Web of Science ®Google Scholar
• Wikimedia Commons [webpage on the Internet]. Germany: Rudolf Virchow; 1902. Available from: https://commons.wikimedia.org/wiki/File:Rudolf_Virchow_(Carl_G%C3%BCnther).png. Accessed July 01, 2020..
   Google Scholar
• Wikimedia Commons [webpage on the Internet]. Germany: Carl vo Rokitanskay Litho; 1853. Available from: https://commons.wikimedia.org/wiki/File:Carl_von_Rokitansky_Litho.jpg. Accessed July 01, 2020.
   Google Scholar